Filters
Revocation of life sciences patents in the UPC
The Unified Patent Court (UPC), active since June 2023, is seeing strong uptake in pharma and biotech. Revocation decisions show a balanced 50:50 win rate for patentees and challengers. Key legal standards on novelty, obviousness, and inventive step are emerging, though some aspects remain unclear. Strategic use of the UPC offers broad enforcement, but revocation risks are higher for single-patent portfolios. Legal uncertainties, like the Bolar exemption, still need clarification.
4 of 5 Insights
Consumer and Retail in the News
Game, set and match! UK's Data (Use and Access) Act passes
The Procurement Act 2023: procurement challenges
Fashion and Luxury Market Update
.png?as=0&dmc=0&iar=0&thn=0&udi=0?as=0&h=182&iar=0&w=375&crop=1&hash=F2775BF2B93112F0E41CD43C8554BD3C)
What have we learned from two years UPC preliminary injunctions?
.png?as=0&dmc=0&iar=0&thn=0&udi=0?as=0&h=182&iar=0&w=375&crop=1&hash=4B3F53F941F2EF34C028C1C2ED7F1793)
UPC and jurisdictional boundaries
Collective actions impacting big tech - Ireland set to test the boundaries in ICCL v Microsoft
Does trying to stop threats of trade mark infringement breach human rights? Bargain Busting v Shenzhen
